Elite in Oligodendroglioma

Francois Ducray

Groupement Hospitalier Est, 
Lyon, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Elite in Oligodendroglioma
Groupement Hospitalier Est, 
Lyon, FR 
OverviewLocationsClinical Research

Overview

Francois Ducray practices in Lyon, France. Mr. Ducray is rated as an Elite expert by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioma, Gliomatosis Cerebri, Oligodendroglioma, and Astrocytoma.

His clinical research consists of co-authoring 199 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles in the study of Oligodendroglioma.

Gender
Male

Locations

Groupement Hospitalier Est, Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.
Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study
Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Radiation, Drug
Study Drugs: TG02, Temozolomide
Study Phase: Phase 1
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Enrollment Status: Completed
Publish Date: April 04, 2022
IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
Enrollment Status: Terminated
Publish Date: February 01, 2022
Intervention Type: Radiation, Drug, Procedure
Study Drug: Temozolomide
Study Phase: Phase 3
Mechanisms of Auto-immune Encephalitis
Mechanisms of Auto-immune Encephalitis
Enrollment Status: Completed
Publish Date: July 29, 2020
Intervention Type: Other
Role of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Patients Wih Leptomeningeal Metastasis of Breast Cancer. A Randomized Phase III Study.
Role of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Patients Wih Leptomeningeal Metastasis of Breast Cancer. A Randomized Phase III Study.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

199 Total Publications

Open questions on vorasidenib.
Open questions on vorasidenib.
Journal: Current opinion in oncology
Published: October 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ducray's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 38 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile